Versant Capital Management Inc Has $652,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

Versant Capital Management Inc increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 842.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,388 shares of the company's stock after purchasing an additional 8,392 shares during the quarter. Versant Capital Management Inc's holdings in Novo Nordisk A/S were worth $652,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its holdings in Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after purchasing an additional 23,223 shares during the last quarter. Bryn Mawr Capital Management LLC grew its position in shares of Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after acquiring an additional 30,420 shares during the period. Clear Creek Financial Management LLC bought a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $450,000. DSM Capital Partners LLC raised its holdings in shares of Novo Nordisk A/S by 16.7% in the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock valued at $172,678,000 after purchasing an additional 286,912 shares during the period. Finally, Channing Global Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $354,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Wall Street Zen raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Finally, Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and a consensus price target of $128.00.

Novo Nordisk A/S Stock Performance

NVO traded up $1.94 on Friday, reaching $71.40. The company had a trading volume of 11,185,051 shares, compared to its average volume of 6,800,832. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The stock has a market cap of $320.41 billion, a P/E ratio of 21.70, a P/E/G ratio of 0.90 and a beta of 0.65. The company's fifty day moving average is $65.58 and its 200 day moving average is $81.59. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion for the quarter. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.